Abstract

The primary goal of the Developmental Research Program (DRP) of the Yale SPORE in Lung Cancer (YSILC) is to identify and fund innovative pilot projects that possess translational potential for making an impact in the field of lung cancer in the areas of risk assessment; early detection; biomarkers for prognosis, therapy, and prediction; biology; and novel treatment approaches. Investigators and projects of funded developmental research projects are strongly encouraged to collaborate with other investigators within and outside of Yale, including other SPORE research communities, with the goal that these projects will evolve into independent full SPORE projects or equivalent scale studies. The objective of the YSILC DRP is to develop innovative lung cancer translational research programs. To achieve this goal, we propose the following three specific aims:
Specific Aim 1. To identify and recruit innovative pilot projects with translational potential for lung cancer.
Specific Aim 2. To support new research opportunities for lung cancer by funding innovative pilot projects.
Specific Aim 3. To enhance collaborations between SPORE full research projects and DRP investigators (current and potential) and to promote DRP projects to potential full SPORE or equivalent scale projects. Pilot projects funded by the DRP mechanism are strongly encouraged to collaborate with intra- and inter- SPORE projects. Projects making significant progress will be considered to be incorporated into a full project if there are any programmatic needs and upon agreement of the YSILC leadership in consultation with the Internal Advisory Board, External Advisory Board and NCI staff.

Public Health Relevance

PROGRAM NARRATIVE The objective of this Developmental Research Program is to foster and develop innovative lung cancer translational research programs with objectives that align with the overall goals of the Yale SPORE in Lung Cancer. Projects of the highest caliber will be sought to possibly serve as replacements for the primary SPORE projects should productivity lag or other unforeseen circumstances arise.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA196530-02
Application #
9149460
Study Section
Special Emphasis Panel (ZCA1-RPRB-7)
Program Officer
Ujhazy, Peter
Project Start
Project End
Budget Start
2016-08-01
Budget End
2017-07-31
Support Year
2
Fiscal Year
2016
Total Cost
$47,249
Indirect Cost

  Institution

Name
Yale University
Department
Internal Medicine/Medicine
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520

  Publications

Hartman, Douglas J; Ahmad, Fahad; Ferris, Robert L et al. (2018) Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. Oral Oncol 86:278-287
Nagarajan, Arvindhan; Malvi, Parmanand; Wajapeyee, Narendra (2018) Heparan Sulfate and Heparan Sulfate Proteoglycans in Cancer Initiation and Progression. Front Endocrinol (Lausanne) 9:483
Rojewski, Alana M; Tanner, Nichole T; Dai, Lin et al. (2018) Tobacco Dependence Predicts Higher Lung Cancer and Mortality Rates and Lower Rates of Smoking Cessation in the National Lung Screening Trial. Chest 154:110-118
Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131
Zhang, Jinhua; Song, Kun; Wang, Jun et al. (2018) S100A4 blockage alleviates agonistic anti-CD137 antibody-induced liver pathology without disruption of antitumor immunity. Oncoimmunology 7:e1296996
Anastasiadou, Eleni; Faggioni, Alberto; Trivedi, Pankaj et al. (2018) The Nefarious Nexus of Noncoding RNAs in Cancer. Int J Mol Sci 19:
Toki, Maria I; Mani, Nikita; Smithy, James W et al. (2018) Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. J Thorac Oncol 13:1884-1896
Park, Seyoung; Zhao, Hongyu (2018) Spectral clustering based on learning similarity matrix. Bioinformatics 34:2069-2076
Gettinger, S N; Choi, J; Mani, N et al. (2018) A dormant TIL phenotype defines non-small cell lung carcinomas sensitive to immune checkpoint blockers. Nat Commun 9:3196
Adams, Brian D; Arem, Hannah; Hubal, Monica J et al. (2018) Exercise and weight loss interventions and miRNA expression in women with breast cancer. Breast Cancer Res Treat 170:55-67

Showing the most recent 10 out of 74 publications